Today: 12 May 2026
Ramp’s $40 Billion Funding Push Could Rewire the Corporate Card Race
11 May 2026
2 mins read

Ramp’s $40 Billion Funding Push Could Rewire the Corporate Card Race

New York, May 11, 2026, 09:06 EDT

According to people familiar with the situation, Ramp is in talks to raise $750 million at a valuation topping $40 billion before the fresh capital comes in, the Wall Street Journal reported. GIC and Iconiq Capital, both existing investors, are expected to co-lead the round, which hasn’t closed yet, the report noted.

The proposed price on the table would push Ramp’s value up by at least 25% from its $32 billion mark last November. That’s just the “pre-money” figure—what investors think Ramp is worth before any new money goes in. If this deal closes, the eventual valuation could come in even higher. PYMNTS.com

The data points to private capital still targeting fintechs touting fast revenue gains, big enterprise uptake, and AI-driven financial automation. Ramp, for one, put its annualized revenue above $1 billion as of November—a 12-month run-rate figure, not audited yearly sales—and counted over 50,000 customers.

Ramp was launched in 2019 by Eric Glyman, Karim Atiyeh, and Gene Lee, making its initial mark with corporate cards and expense software. The company’s reach has since widened—now covering procurement, travel booking, bill pay, treasury management, and accounting automation—as it transitions from a card-focused offering to a more comprehensive finance operations platform.

AI is front and center at the company. Ramp rolled out its AI agents for procurement on April 29, touting features like automated triage for employee purchase requests, vendor sourcing, contract review, and compliance checks. “The tools companies use to buy haven’t kept pace with the speed or sophistication of what they’re buying,” said Geoff Charles, Ramp’s chief product officer, in the company’s statement. PR Newswire

Ramp’s ascent has outpaced the typical late-stage startup trajectory. Back in July, Reuters reported that Ramp landed $500 million at a $22.5 billion valuation—Iconiq led the round—just a month after the company was pegged at $16 billion. Then in November, Ramp went on to announce its $32 billion round.

Michael Ashley Schulman, chief investment officer at Running Point Capital, described Ramp’s rapid jump in valuation to Reuters as “another indicator that the fintech ice age has thawed.” That’s particularly true, he noted, for firms “already printing cash” and selling AI-driven products tailored to finance chiefs. “Pair positive cash flow with a credible AI story and your valuation can ramp fast,” he said. Reuters

Glyman is positioning Ramp’s pitch on cutting down bloat in corporate spending. “Our goal is to make every customer more profitable,” he said in Ramp’s November release. According to the company’s internal data, customers who move to Ramp typically spend less and see faster growth. PR Newswire

If Ramp manages to close the funding, it would have extra firepower to target bigger enterprise clients and hold its ground in a competitive space. The company faces rivals like Brex and Stripe on the payments and expense side, plus established names such as American Express and SAP with deep roots in corporate finance teams.

The deal remains unresolved. TechCrunch reported that terms are still in flux, and Ramp wouldn’t comment. That lofty private valuation? It doesn’t leave much room if growth stumbles, customers don’t see promised AI savings, or large rivals start squeezing prices.

Right now, those fundraising discussions show investors remain ready to put a premium on a fintech pitching smoother operations for finance departments. The bigger challenge kicks in after that higher valuation—demonstrating the software can continue removing friction from corporate spend, without piling on new risk or headaches.

Stock Market Today

  • QuantumScape Shares Rise 11.7% on Eagle Line Launch and Initial Billings
    May 12, 2026, 5:46 PM EDT. QuantumScape (QS) gained 11.7% following the launch of its Eagle Line pilot-scale solid-state battery cell facility and initial $11 million in customer billings from ecosystem partners. The company reported a narrower GAAP net loss in Q1 2026, driven by reduced operating expenses. This marks a shift toward early commercialization and a potential licensing and royalty revenue stream, altering QuantumScape's risk profile and business model. Investors remain cautious as success depends on partner uptake and scaling production. Analysts' revenue forecasts vary widely, reflecting uncertainty around the new manufacturing blueprint. QuantumScape projects $544.5 million revenue and $33.3 million earnings by 2029, but some estimates are much lower, highlighting diverging market views.

Latest article

British American Tobacco Stock Jumps as FDA Shift Gives Vuse and Velo a Cleaner Read

British American Tobacco Stock Jumps as FDA Shift Gives Vuse and Velo a Cleaner Read

12 May 2026
British American Tobacco shares jumped 5.82% in London to £46.34 after the FDA signaled a softer enforcement stance on some e-cigarette and nicotine pouch products. A U.S. judge also dismissed BAT’s North Korea sanctions case following a $630 million settlement. The FTSE 100 slipped 0.04%. BAT’s U.S.-listed ADR closed up 5.3% at $63.64.
Camtek Stock Falls 16% After Earnings Beat as Margin Pressure and Hot CPI Hit AI Chip Trade

Camtek Stock Falls 16% After Earnings Beat as Margin Pressure and Hot CPI Hit AI Chip Trade

12 May 2026
Camtek shares fell 15.8% to $174.63 despite beating Q1 revenue and adjusted EPS estimates by small margins. Q1 revenue rose 2.5% year over year, but non-GAAP EPS dropped to $0.70 from $0.79 and operating margin narrowed to 25.5%. Management guided Q2 revenue to $129–$131 million and expects second-half revenue to rise over 25%. Broader market pressure followed a hot April CPI and rising Treasury yields.
Oscar Health stock rises in premarket after 2026 revenue outlook; House subpoenas add a fresh risk

Oscar Health Stock Extends Post-Earnings Repricing as Margins Outweigh ACA Risk

12 May 2026
Oscar Health shares rose 7.9% to $23.73 late Tuesday, with volume near 13 million, after posting strong Q1 profit and lower claims costs despite missing revenue estimates. The company’s medical loss ratio fell to 70.5% from 75.4% a year earlier. Membership climbed to 3.17 million. ACA enrollment churn and policy risk remain concerns.
Lumentum’s Nasdaq-100 Breakthrough Turns AI Optics Stock Into Must-Watch Index Trade
Previous Story

Lumentum’s Nasdaq-100 Breakthrough Turns AI Optics Stock Into Must-Watch Index Trade

GCT Semiconductor Stock Moves Before Q1 Earnings as Satellite 5G Deal Raises Stakes
Next Story

GCT Semiconductor Stock Moves Before Q1 Earnings as Satellite 5G Deal Raises Stakes

Go toTop